Abstracts tagged "Nuclear Medicine"

Abstract Number: 1550 • ACR Convergence 2022
Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
SEMA KAYMAZ-TAHRA¹, Salih Ozguven², Nuh Filizoglu², Ali Ugur Unal³, Fatma Alibaz-Oner⁴, Tunc Ones², Tanju Yusuf Erdil² and Haner Direskeneli⁵, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ³Marmara University School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Iliofemoral artery disease, which is commonly observed in severe atherosclerosis, may also be present in Takayasu's arteritis (TAK). In this study we aimed to…
Abstract Number: 1977 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Jonathan Graf¹, Martin Jacobs², Debbie Gladd-Foley³, Yelliann Ruiz-Irizarry⁴, Alan Kivitz⁵, Melvin Churchill⁶, Arash Kardan⁷, Mara Leach⁸, David Ralph⁸, Nicole Korczak⁸, Addison Hasselbach⁸, Bonnie Abbruzzese⁸, Rachael Hershey⁸, Beth Potter⁸, Jessica Fitzpatrick⁸, Aaron Thornton⁸, Michael Blue⁸ and Michael Rosol⁸, ¹Ucsf, San Francisco, CA, ²Kettering Network Radiologists, Kettering, OH, ³Premier Rheumatology of Oklahoma, Tulsa, OK, ⁴Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, ⁷Baylor College of Medicine, Department of Radiology, Houston, TX, ⁸Navidea Biopharmaceuticals, Dublin, OH
Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 0174 • ACR Convergence 2021
Imaging Neoangiogenesis in Rheumatoid Arthritis II (INIRA II): Whole-body Synovial Uptake of 99mTc-Maraciclatide Correlates with Power Doppler Ultrasound and Serum Neoangiogenic Biomarkers
Laura Attipoe¹, Sujith Subesinghe², Cristina Blanco Gil², Maria Opena², Kathryn Steel³, Sarah Ryan³, Sam Norton³, Mark Rosser⁴, Gary Cook³, Andrew P Cope³ and Toby Garrood², ¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, London, ³King's College London, London, United Kingdom, ⁴Serac Healthcare, London, United Kingdom
Background/Purpose: 99mTc-maraciclatide (99mTc-M) (Serac Healthcare) is a radio-labelled tracer which binds with high affinity to integrin αvβ3, a cell-adhesion molecule up-regulated on neoangiogenic blood vessels.…
Abstract Number: 0428 • ACR Convergence 2020
Enrichment of Clinical Trial Recruitment Using Advanced Molecular Imaging in Takayasu’s Arteritis
Kaitlin Quinn¹, Mark Ahlman², Emily Rose³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ³Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Definitions of disease activity are not standardized in Takayasu’s arteritis (TAK), which can lead to difficulty in determining whether a patient should be enrolled…
Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 1580 • ACR Convergence 2020
Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
David Liew¹, Aurora Poon², Christopher McMaster³, Claire Owen⁴, Jessica Leung⁵, Albert Frauman², Jonathan Cebon⁶, Andrew Scott⁶ and Russell Buchanan⁷, ¹Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia, ²Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Ashburton, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, ⁶Austin Health, Melbourne, Victoria, Australia, Melbourne, Australia, ⁷Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia
Background/Purpose: The pathogenesis of rheumatic immune-related adverse events (irAEs) from checkpoint inhibitor cancer immunotherapy directed against programmed cell death protein 1 (PD-1) and programmed death…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].